ICS/LABA safe and cut exacerbations: FDA explains why ‘black box’ removed

Members of an FDA safety committee have explained why they took the unusual step of removing ‘black box’ safety warnings from combined inhaled corticosteroid-long acting beta agonist inhalers in December 2017. The warnings were originally put in place in 2011 as a precautionary measure after some trials involving LABA-containing inhalers suggested an increased risk of ...

Already a member?

Enter your email to keep reading.